# Enliven Therapeutics, Inc.: Form 8-K, filed Mar 3, 2026

- Company: [Enliven Therapeutics, Inc.](/companies/elvn.md) (CIK 1672619)
- Form: 8-K
- Filed: 2026-03-03
- Accepted by EDGAR: Mar 3, 2026, 16:10 ET
- Period: 2026-03-03
- Accession: 0001193125-26-088195
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1672619/000119312526088195/elvn-20260303.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1672619/000119312526088195/

## Items reported

- Item 2.02: Results of operations
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1672619/000119312526088195/elvn-20260303.htm

Filed Mar 3, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-088195. Last ingested by Listed: Nov 5, 2026, 17:49 ET. No prices; not investment advice.
